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Abstract Phage antibodies have been widely prospected as an
alternative to the use of monoclonal antibodies prepared by
traditional means. Many monoclonal antibodies prepared against
peptides are able to recognise the native proteins from which they
were derived. Here we show that the same is also true for phage
antibodies. We have selected a number of single-chain variable
fragments (scFv) from a large phage scFv library against a
peptide from the switch region II of p21Ras. This peptide is
known to reside in a mobile area of the native protein and is the
epitope of a well characterised monoclonal antibody. Selected
scFvs were able to recognise native p21Ras in both ELISA and
Western blots, indicating that peptides are also likely to be very
useful in selecting from phage antibody libraries.
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1. Introduction
The immunisation of animals with peptides has long been
used to isolate antibodies against the native proteins from
which they were derived (reviewed in [1,2]). This technique
is especially useful when the native protein is di⁄cult to pre-
pare or purify in su⁄cient quantities to allow immunisation,
and is based on the initial observations of Anderer that anti-
bodies raised against tobacco mosaic virus peptides could rec-
ognise the native protein [3,4]. Since then, a number of di¡er-
ent authors have attempted to derive rules which allow the
prediction of peptides which are more likely to elicit antibod-
ies recognising the native protein. Individual parameters
which have been shown to in£uence such peptide antigenicity
include hydrophilicity [5], L-turn tendency [6,7], amphipathic-
ity [8], surface exposure [9] and segmental mobility [10].
The rules governing peptide antigenicity take into account a
complete immune system with functioning T and B cells. It
has recently proved possible to derive antibodies in vitro
against a large number of antigens from phage antibody li-
braries [11^16] in which antibodies are displayed on the sur-
face of ¢lamentous phage and selected on the basis of their
binding activity to the antigen. As cells of the immune system
are absent, the antibodies selected recognise the antigen as it is
presented to the library and not after processing by the im-
mune system.
The ability to select antibodies against peptides which rec-
ognise the native protein from these libraries has been tested
with a 20 amino acid MUC1 peptide which corresponds to a
repeated antigenic epitope in MUC1 mucin [17]. In this case a
single antibody was isolated and shown to recognise the full-
length protein. This is, however, a special case, since the epi-
tope is repeated, and may not be applicable to all peptides.
The p21Ras protein is a small GTPase, which cycles be-
tween a GTP-bound active and GDP-bound inactive form,
involved in many signal transduction pathways [18,19]. The
active and inactive forms have di¡erent structures, caused by
a large conformational change in the two switch regions
(switch I: Asp-30^Asp-38 and switch II: Gly-60^Glu-76)
which £ank the guanine nucleotide binding pocket (reviewed
in [20]). This conformational change allows the active form of
p21Ras to interact with downstream e¡ector proteins such as
Raf-1, B-raf, PI-kinase and RalGDS [21] and so transmit
signals into the cell from the surface.
The purpose of this work was to use phage display to derive
new antibodies against p21Ras using the peptide approach;
these to be used later for intracellular expression to interfere
with p21Ras function (intracellular immunisation) [22]. Given
the known mobility of switch region II and the fact that an
antibody (Y13-259 [23]) which recognises this region [24] has
been shown to be able to neutralise Ras function by antibody
microinjection [25^27], and intracellular expression [28^31],
we selected antibodies against the 57^76 peptide from a large
phage display single-chain variable fragment (scFv) library
[13]. This was presented to the antibody library in two di¡er-
ent ways: as conjugated to bovine serum albumin (BSA) and
displayed on the Escherichia coli cell surface within the outer
membrane protein LamB (LamB-Ras) [32], a context in which
it was previously shown to be capable of acting as a selector
in a model system.
2. Materials and methods
2.1. Plasmids and library
4DJ [33] is a plasmid containing a p21Ras(57^76) epitope cloned
(recognised by the mAb Y13-259) into the BamHI site of pAJC264
[34], a prokaryote expression plasmid, which allows the expression of
foreign epitopes within one of the exposed loops of the LamB protein
[35]. The clone BW2029 is an E. coli N6105 strain harbouring a
temperature-sensitive V-repressor controlling expression of p21Ras
from pJCL-E30 [36]; it was provided by B. Willumsen (University
of Copenhagen) and was used to produce p21Ras protein according
to [33].
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The phage display library is characterised by 6.7U109 members of a
naive human antibody repertoire, cloned in the pHEN1 vector [37]
and displayed as scFvs [13]. pUC119 S¢-NotmycHis [38] is a bacterial
vector for the expression of scFvs with a hexa-histidine tag on their C-
termini. The phage library and the pUC119 S¢-NotmycHis vector
were kind gifts of Jim Marks.
2.2. Preparation of selectors
BSA-peptide conjugation was performed by the glutaraldehyde cou-
pling procedure [1] which employs NH2 and SH groups for coupling.
Since there are no lysines or cysteines present in the amino acid
sequence of the peptide, the peptide should be coupled to BSA via
its amino terminus, so preserving its secondary structure and antigenic
activity. The Ras peptide 57^76 (DTAGQEEYSAMRDQYMRTGE,
synthesised in ICGEB, Trieste) was added to a 1 mg/ml solution of
BSA in phosphate bu¡ered saline (PBS) pH 7.4, at molar ratios of
protein to peptide varying from 1 to 20. When the mixture was cooled
by keeping on ice, a 2% glutaraldehyde solution was added in an
equal volume to the protein mixture with constant stirring. After 1 h
the reaction was stopped by addition of sodium borohydride (NaBH4)
to a ¢nal concentration of 10 mg/ml. The reaction mixture was dia-
lysed against three changes of PBS and stored in aliquots at 320‡C.
The clone 4DJ was used for preparation of LamB-Ras(57^76) bac-
teria [32].
2.3. Selection
Immunotubes were coated overnight at 4‡C with 10 Wg/ml of BSA-
Ras(57^76) peptide in 100 mM carbonate bu¡er (pH 9.4), blocked for
1 h at room temperature with 2% skimmed milk powder in PBS (2%
MPBS). The ¢rst cycle of selection was performed using 1013 phage in
1 ml of MPBS left in contact with the antigen in the immunotube for
1 h at room temperature. Phage were washed 20 times in PBS+Tween
20 (0.05%) and 20 times in PBS. Phage were eluted in 100 mM tri-
ethylamine for 10 min and neutralised by the addition of Tris 1 M
pH 8 [12].
The selection of the library on the LamB-Ras(57^76) selector was
performed in two ways: directly and with a depletion step for 4 h on
non-recombinant bacteria before each cycle of selection.
The selection was performed on 300 Wl of bacterial suspension
(equivalent to 30 Wl of bacterial pellet and approximately 3U109
bacteria). The selection procedure was the same as described above,
except that the ¢xed bacteria were centrifuged for 5 min at 5000 rpm
at room temperature between washing cycles.
When depletion was applied before each cycle of phage binding to
the ¢xed bacteria displaying the epitope, the phage were incubated on
1 ml of ¢xed DH5K bacterial suspension for 2 h on the rotating wheel
at room temperature. After centrifugation (for 5 min at 5000 rpm) the
supernatant containing unbound phage was employed for binding to
the bacteria displaying the epitope.
2.4. Screening for unique binders
BSA-Ras(57^76) binding was determined by ELISA using soluble
scFvs [12]. The coating and saturation of microtitre plates were done
in the same way as for selection in immunotubes. After incubation
with the soluble scFvs, wells were incubated with the anti-myc mouse
monoclonal antibody, 9E10 [39] and with a 1:2000 dilution of an anti-
mouse-HRP (horseradish peroxidase) conjugate (Dako). Binding was
revealed with TMB (tetramethyl benzidine) and stopped with 1 M
sulphuric acid.
The number of unique scFvs was estimated by PCR ¢ngerprinting
using BstNI as described in [12].
2.5. scFv puri¢cation and a⁄nity measurements
The selected scFv genes were subcloned into the bacterial expres-
sion vector pUC119S¢-NotmycHis, expressed, harvested from the
periplasm [40] and puri¢ed by immobilised metal a⁄nity chromatog-
raphy [41]. To separate monomeric scFvs from dimeric and aggre-
gated scFvs, samples were fractionated on a Superdex 75 column
using PBS as running bu¡er in a Biologic (Bio-Rad). scFv concentra-
tions were quanti¢ed with the micro-BCA kit (Pierce).
scFv dissociation equilibrium constants (Kd) were calculated from
the association (kon) and dissociation (koff ) rate constants determined
using surface plasmon resonance in a BIAcore 2000 instrument (Bia-
core AB, Uppsala, Sweden). Using standard amine coupling as de-
scribed in the Biacore manuals, approximately 1200 RU of BSA-
Ras(57^76) was coupled to a CM5 sensor chip (Pharmacia). These
amounts of coupled antigen yielded scFv RUmax of approximately 400
RU. Association rate constants were measured using scFv concentra-
tions in the appropriate range (around Kd values). Calculation of Kd
values was performed by ¢tting the data according to a single-site
model, using the BIAevaluation 2.1 software. Where possible, associ-
ation rate constants were determined from secondary plots (ks versus
concentration).
2.6. Western blot
The clone BW2029 was grown and induced according to [33]. In-
duced bacteria were treated with sample bu¡er, boiled and run on
SDS-PAGE, and then blotted onto nitrocellulose sheets. These were
cut into 5 mm strips. Soluble scFv proteins were expressed, harvested
from the bacterial periplasm [42] and incubated with the nitrocellulose
strips, overnight at +4‡C. Washings were performed with PBS+0.05%
Tween 20 and saturation with 2% MPBS. The nitrocellulose strips
were incubated at room temperature for 1 h with the 9E10 monoclo-
nal antibody, washed and incubated for 1 h with a 1:1000 dilution of
an anti-mouse-AP (alkaline phosphatase) conjugate (Dako). Binding
was revealed with BCIP (5-bromo-4-chloro-3-indolyl-phosphate) and
NBT (nitroblue tetrazolium) chromogenic substrate.
2.7. Native Ras ELISA
p21Ras was puri¢ed according to the method described in [43]. The
GTPase activity of the recombinant p21Ras was checked using the
method described in [44]. Puri¢ed p21Ras (100 ng) was coated in
carbonate bu¡er overnight at 4‡C, washed 3 times with TBS (Tris
20 mM pH 7.4, NaCl 150 mM) and blocked with 3% BSA in TBS
for 1 h at 37‡C. Subsequently wells were washed once with TBS and
undiluted periplasmic fractions were incubated for 1 h at 37‡C. Wells
were washed with TBST (TBS containing 0.01% Tween 20) and in-
cubated with biotinylated mAb 9E10 for 1 h at 37‡C. Wells were
washed with TBST and incubated with HRP/streptavidin (1:5000
Dako) for 15 min at room temperature. After washing, wells were
stained with TMB and stopped with 1 M sulphuric acid. Absorbances
were measured at 450 nm.
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Table 1
(A) Elution pro¢les from the phage antibody library selected on the indicated selectorsa and (B) screening of anti-Ras(57^76) clones derived
from the third cycle of selection on the indicated selectorsb
(A) Selector Phage recovery (%)
1st cycle 2nd cycle 3rd cycle
BSA-Ras(57^76) 1.6U1038 1.3U1036 4U1035
LamB-Ras(57^76) bacteria (without depletion) 2.5U1034 8.3U1034 0.23
LamB-Ras(57^76) bacteria (with depletion) 5.8U1035 2.5U1033 1
(B) Selector Positives (%) Unique clones
BSA-Ras(57^76) 25.0 7
LamB-Ras(57^76) bacteria (without depletion) 6.5 1
LamB-Ras(57^76) bacteria (with depletion) 4.3 3
aPhage recovery in every cycle is indicated as percentage of phage eluted compared to those loaded.
bPeptide Ras(57^76) binders, as detected by BSA-Ras(57^76) ELISA, are indicated as percentages of positives on total number of 100 analysed
clones; unique clones among binders are determined by BstNI ¢ngerprinting.
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3. Results
The Ras peptide chosen (57^76) for selection is K-helical
within the context of the p21Ras protein [20], and changes
its orientation upon activation (see [45] for discussion and
references). The secondary structure of the free peptide is
also likely to be K-helical on the basis of structural predictions
using Predict-Protein (Heidelberg) [46,47] and molecular me-
chanics [47,48] and dynamics [49] calculations. This structural
maintenance and the known conformational mobility of this
segment represent a valuable prerequisite for its use as poten-
tial selector.
The phage library [13] was selected on two selectors: BSA-
Ras(57^76) and LamB-Ras(57^76) bacteria. LamB-Ras(57^
76) bacteria were used as it has been demonstrated that the
antibody Y13-259, the derived scFv, and a phage displaying
Y13-259 scFv are speci¢cally able to recognise the Ras neu-
tralising epitope when displayed within the context of the out-
er membrane protein, LamB [32,33]. Moreover, the LamB-
Ras(57^76) bacteria column was shown to be e¡ective in se-
lecting speci¢c phage-antibody binders from a non-binder
background [32]. One problem in the use of bacteria display-
ing epitopes on their surface is the possibility of selecting
antibodies against natural epitopes found on the bacterial
cell surface. Therefore in addition to direct selection on
LamB-Ras(57^76) bacteria, a depletion procedure, which in-
volved preincubating the library on wild type bacteria before
each cycle of selection on LamB-Ras(57^76) bacteria, was also
used. The BSA-Ras(57^76) selector was made by coupling the
Ras peptide to BSA at an epitope density of 1:20. The selec-
tions on BSA-Ras(57^76), LamB-Ras(57^76) bacteria and
LamB-Ras(57^76) bacteria with depletion were performed
with three cycles of binding and elution. The elution pro¢les
are presented in Table 1A. In all three cases, a steady enrich-
ment of phage from each of the selectors with increasing
cycles is seen.
Phage clones derived from the third cycle of all three selec-
tions were analysed for their ability to bind BSA-Ras(57^76)
in an ELISA. In all three cases anti-Ras peptide binders were
identi¢ed. The percentages of unique clones among binders, as
determined by BstNI ¢ngerprint analysis [50] of the PCR
ampli¢ed scFv gene, are presented in Table 1B. The use of
bacteria resulted in a much lower number of clones able to
recognise BSA-Ras(57^76) when compared to the use of BSA-
Ras(57^76) as a selector. This is likely to be due to the simul-
taneous selection of antibodies against bacterial epitopes, as
described above. Selection on bacteria did not appear to be
greatly in£uenced by prior depletion, in that in both cases
anti-peptide Ras antibodies with similar a⁄nities (see later)
were selected.
In order to produce su⁄cient quantities of the scFvs for
further analysis, each of the anti-Ras(57^76) scFvs was sub-
cloned into the vector pUC119 S¢-NotmycHis, which elimi-
nates g3p and adds a hexa-histidine tag at the C-terminus of
the scFv [51]. After puri¢cation by metal a⁄nity chromatog-
raphy (IMAC) and fractionation by gel ¢ltration, the mono-
meric scFv fractions were subjected to a⁄nity (Kd) measure-
ments using surface plasmon resonance in a BIAcore 2000
instrument (Biacore AB, Uppsala, Sweden). It proved impos-
sible to carry out this technique with native p21Ras, as the
epitope recognised by these antibodies (including Y13-259)
appears to be masked when p21Ras is immobilised on the
BIAcore chip (data not shown), therefore measurements
were performed using immobilised BSA-Ras(57^76) conju-
gate. As shown in Table 2, the Kd of the anti-Ras(57^76)
scFvs ranged from 5.4 to 803 nM.
In order to test the cross-reactivity of the selected anti-
Ras(57^76) scFvs proteins with full-length p21Ras protein
two approaches were taken: Western blotting with p21Ras
and an ELISA using native p21Ras. The Western blot was
performed with p21Ras expressed in E. coli (clone BW2029)
and using soluble scFv proteins harvested from the periplasm
[40]. As shown in Fig. 1, all scFvs analysed (except E3 and
A1) are able to recognise a band corresponding to a molecular
weight of 21 kDa in Western blots. While these experiments
indicated that the selected scFvs could recognise denatured
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Fig. 1. Recognition of the bacterially produced p21Ras by the se-
lected anti-Ras(57^76) scFvs. Kphox: anti-phenyloxasolone scFv
which does not recognise p21Ras The molecular weight markers are
given in kDa.
Table 2
A⁄nity measurements of the anti-Ras(57^76) antibodies on BSA-Ras(57^76) using BIAcore 2000
Selector Antibody kon (M31 s31) koff (s31) Kd (nM)
Y13-259 scFv 1U105 1.6U1032 160
BSA-Ras(57^76) A1 1.8U106 9.7U1033 5.4
B12 3.1U106 3.3U1032 10.7
C12a ND 2.1U1033 ND
D5 1.6U106 7.5U1032 46.9
E7 8.5U104 2.7U1032 318
E11 1.3U106 1.1U1032 8.5
G1 5.5U104 1U1032 182
LamB-Ras(57^76) (without depletion) B5 7.1U104 5.7U1032 803
LamB-Ras(57^76) (with depletion) E3 3.5U104 9.1U1033 260
The table summarizes kon and koff constants, together with the calculated equilibrium dissociation constants (Kd).
aThe clone demonstrates atypical kinetics during the association phase, therefore it was not possible to determine the association rate constant.
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p21Ras in a Western blot, it gives no indication of their ability
to recognise native p21Ras. This was shown for most clones
by ELISA on native p21Ras (Fig. 2), in which some scFv
(C12, D5, E7 and E11) gave ELISA signals far stronger
than the positive control scFv Y13-259. Surprisingly, even
though the scFv A1 is able to recognise the Ras peptide in
the BIAcore, it does not interact with p21Ras or the Ras
peptide in ELISA.
4. Discussion
Antibodies have been used in a wide range of applications
such as in vitro and in vivo diagnostics, in passive immunisa-
tion, as therapeutics, in research, and more recently in intra-
cellular immunisation. They have been routinely obtained by
animal immunisation or by hybridoma technology. The use of
phage antibody libraries has proved to be a quick and reliable
alternative source of monoclonal antibodies, speci¢c for a
wide range of antigens, from diverse species, including self-
antigens [12,14,15,17]. However, a successful animal immuni-
sation or library selection relies on the availability of a puri-
¢ed and conformationally correct antigen. This is usually ob-
tained after puri¢cation of cloned fusion proteins. Although
antibodies against cloned gene products have been success-
fully raised in animals and selected from libraries [13,14,52],
some proteins are poorly expressed in bacteria and may pre-
cipitate, causing problems in subsequent selection. This is
likely to be particularly true for proteins such as integral
membrane proteins, or cytoplasmic proteins, such as
p21Ras, residing in speci¢c cellular environments. These prob-
lems are likely to be especially di⁄cult to overcome when
faced with the need to select antibodies destined for intracel-
lular immunisation.
The purpose of this work was to derive antibodies against
p21Ras, to be used for intracellular expression to interfere
with its function. As p21Ras is a highly conserved self-protein,
the attempt to isolate antibodies against it was done by selec-
tion from a large naive and diverse phage antibody library
[13], using the peptide 57^76, in di¡erent forms, as selector.
It has been postulated that peptides in solution can assume a
wide number of conformations, of which one predominates
[1]. By molecular dynamics and mechanics it was shown
that the 57^76 free peptide was expected to mimic the K-helix
it adopts within the protein (discussed in [45]). For library
selections, two approaches to selection were taken: the free
peptide was conjugated to BSA and coated on immunotubes,
and the peptide was displayed on bacterial cell surfaces within
the context of the outer membrane protein LamB.
Antibodies were selected against the Ras peptide on both
formats (Table 1A) and in all selections anti-Ras peptide bind-
ers were identi¢ed (Table 1B). Many more di¡erent antibodies
(as manifested by di¡erent PCR ¢ngerprints) were obtained
when using BSA-Ras(57^76) as selector rather than LamB-
Ras(57^76) bacteria (Table 1B).
The binding a⁄nities of the selected scFvs measured on the
BIAcore ranged from 5.4 to 803 nM (Table 2). Unfortunately,
a⁄nities on p21Ras could not be measured as the epitope is
masked upon binding to the chip (data not shown).
Anti-peptide antibodies are often able to recognise the de-
natured parental protein very well [1] and this is true for the
majority of the isolated anti-peptide antibodies which were
able to reveal p21Ras in Western blots in which whole bacte-
rial extracts containing p21Ras were loaded (Fig. 1). The clear
signal obtained in Western blots indicates the high speci¢city
of these antibodies for their antigen, as no other bands are
visualised.
The majority of the scFvs selected were also able to recog-
nise native p21Ras in an ELISA in which native p21Ras was
coated on the plastic surface, with some of the scFvs (C12,
D5, E7 and E11) giving signals far higher than the positive
control scFv Y13-259 (Fig. 2). There is no correlation between
the a⁄nities for the BSA-Ras peptide as determined by BIA-
core and the ELISA signals obtained on native p21Ras. This
is likely to be due to a number of di¡erent factors, including
susceptibility of the detection tag to proteolysis, the use of
di¡erent antigens and di¡erent immobilisation protocols.
These scFvs were selected for use in intracellular studies.
Preliminary data have shown that some of these clones (S.
Biocca et al., manuscript in preparation), as well as Y13-259
[31], are able to inhibit DNA synthesis in 3T3 NIH trans-
formed cells when expressed within the cytoplasm, analogous
to similar results obtained with microinjection of Y13-259
scFv [25]. Should intracellular antibodies ¢nd a role in cancer
therapy, the fact that they are of human origin is likely to be
of great advantage.
We have shown that it is possible to use peptides to select
antibodies from phage antibody libraries which recognise the
native protein. This is a result analogous to those which have
been previously obtained with peptide immunisation in exper-
imental animals. However, the use of phage antibodies avoids
the involvement of cell-mediated immunity. This is likely to
play a role in the composition and sequence of peptides which
are able to select antibodies recognising the native protein. An
analysis of the factors which determine the ‘immunogenicity’
of a peptide within the context of phage antibody selection is
likely to be very important in the selection of multiple anti-
bodies against the protein products of genes identi¢ed in the
human genome project. In most cases, the protein is not avail-
able in su⁄cient quantity for conventional chemical studies or
its presence in the cell may even be in doubt. By synthesising
peptide fragments of the putative protein and selecting anti-
bodies against it, it may be possible to isolate and characterise
the native protein using appropriate immunoassays. Selection
using recombinant bacterial columns may also be useful in
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Fig. 2. Solid-phase p21Ras ELISA. Absorbance signals given by
periplasmic space preparations of single scFv clones on solid-phase
coated p21Ras (grey bar), BSA-Ras(57^76) (black bar) and BSA
(white bar) are given. Kphox: anti-phenyloxasolone scFv.
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those cases when synthetic peptides cannot be easily synthes-
ised.
Restricted phage-antibody libraries derived by selection
against peptides may be screened against native antigens in
situ by intracellular expression, using the yeast two-hybrid
system or by conferring a phenotype after intracellular expres-
sion. The latter case is elegantly described in [53], where the
expression of an antibody fragment against the Moloney
mouse leukaemia virus reverse transcriptase leads to selective
survival of the virus infected cells.
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